

## Pharmacokinetics-Pharmacodynamics (PK-PD) Target Attainment Analyses to Support ZTI-01 (Fosfomycin for Injection) Dose Selection for Patients with Complicated Urinary Tract Infections (cUTI)

S. M. Bhavnani<sup>1</sup>, M. Trang<sup>1</sup>, C. M. Rubino<sup>1</sup>, A. J. Lepak<sup>2</sup>, D. R. Andes<sup>2</sup>, R. K. Flamm<sup>3</sup>, K. Sweeney<sup>4</sup>, E. J. Ellis-Grosse<sup>4</sup>, P. G. Ambrose<sup>1</sup>

<sup>1</sup>Inst. for Clinical Pharmacodynamics Inc., Schenectady, NY

<sup>2</sup>Wisconsin Univ., Madison, WI

<sup>3</sup>JMI Lab., N. Liberty, IA

<sup>4</sup>Zavante Therapeutics, Inc., San Diego, CA


**Background:** ZTI-01, fosfomycin for injection, has *in vitro* activity against Gram -positive and -negative organisms, including carbapenem-resistant Enterobacteriaceae. ZTI-01 is currently in Phase 2/3 development for the treatment of patients with cUTI. PK-PD target attainment analyses were undertaken to provide support for the ZTI-01 dosing regimen to treat patients with cUTI.

**Methods:** Using parameter estimates from a population PK model (3-compartment model with zero-order input and 1<sup>st</sup>-order elimination), total-drug plasma concentration-time profiles were generated for 6000 simulated patients with varying creatinine clearance (CL<sub>cr</sub>, mL/min/1.73m<sup>2</sup>). Simulated patients received ZTI-01 according to CL<sub>cr</sub>: 6 g IV q8h for > 50 mL/min/1.73 m<sup>2</sup>, 4 g IV q8h for >40 to 50 mL/min/1.73 m<sup>2</sup>, 6 g IV loading followed 3 g IV q8h for >30 to 40 mL/min/1.73 m<sup>2</sup>, and 6 g IV load followed by 5 g IV q24h for >10 to 30 mL/min/1.73 m<sup>2</sup>. Day 1 AUC<sub>0-24</sub> was calculated. Percent probabilities of PK-PD target attainment by MIC and overall (i.e., weighted over the MIC distribution for 1091 Enterobacteriaceae isolates from the USA) were determined using median total-drug plasma AUC:MIC ratio targets associated with net bacterial stasis and a 1- log<sub>10</sub> CFU reduction from baseline at 24 h from a neutropenic murine- thigh infection model for Enterobacteriaceae (19.1 and 41.6, respectively).

**Results:** Percent probabilities of attaining PK-PD targets associated with net bacterial stasis (Figure 1) and a 1 log<sub>10</sub> CFU reduction were ≥98.3% at a MIC=64 mg/L and ≥97.3% at a MIC=32 mg/L, respectively, across renal function groups. These MIC values were 1 to 2 dilutions higher than the MIC<sub>90</sub> of 16 mg/L for Enterobacteriaceae. Overall percent probabilities of PK-PD target attainment for each target were 97.8 and 95.5%, respectively.

**Conclusions:** Together with clinical outcome data, these data will provide support for ZTI-01 dosing recommendations and fosfomycin susceptibility breakpoints for Enterobacteriaceae.

**Figure 1.** Percent probabilities of PK-PD target attainment by MIC based on the AUC:MIC ratio target associated with net bacterial stasis among simulated patients by renal function group after administration of ZTI-01 6 g q8h-based dosing regimens, overlaid on the fosfomycin MIC distribution for Enterobacteriaceae



Keywords: fosfomycin, pharmacokinetics/pharmacodynamics, ZTI-01

Sub-track: AAID03 Antimicrobial pharmacokinetics, pharmacodynamics and general pharmacology